All of our C-level executives have deep expertise in skin science and pharmaceutical innovation. In fact, they developed one of the world’s most respected dermatological skincare brands, SkinMedica. Together they created a team of smart, savvy and experienced women and partnered with the country’s most respected skin physicians.

This collaboration resulted in Colorescience - a truly skin-first line of prestige makeup that gives women the luxurious colors, textures, and finishes they expect from high-end cosmetics while delivering the science of healthy skin.

We believe beauty can be a healthy proposition. We know every woman, including ourselves, deserves cosmetics that beautify AND nourish AND protect, all at once, every single time. We are committed to creating a trustworthy beauty line that makes skin look gorgeous today, tomorrow and beyond.

Colorescience Corporate Team

Mary Fisher

Mary Fisher Chair & Chief Executive Officer

Mary Fisher is Chair, Chief Executive Officer and Board Director at Colorescience, a former division of SkinMedica Inc., where she served as Chief Executive Officer from 2008 until 2012. She led the successful sale of the company to Allergan, Inc. for $350 million with the potential for another $25 million contingent on certain sales milestones. Ms. Fisher has more than 30 years in the pharmaceutical and biotechnology industries, including management and leadership positions at Acorda Therapeutics, Cephalon, Immunex and Boehringer Ingelheim. She is on the board of directors of Ovascience and MDRejuvena. In 2013, Ms. Fisher was honored as Ernst & Young's Entrepreneur of the Year for San Diego and also received the EY Venture Capital Award of Excellence.

Ted Ebel

Ted Ebel Chief Business Officer

Ted Ebel serves as Chief Business Officer at Colorescience. Mr. Ebel has 20 years of experience in the health, wellness and consumer products industries. Prior to Colorescience, Mr. Ebel was Senior Vice President of Corporate Development for SkinMedica, Inc. having responsibility for mergers and acquisitions, licensing, intellectual property management, market research and establishing the company's international operations. Earlier in his career, Mr. Ebel served as the Executive Director of Corporate Development at CancerVax Corporation, a biotechnology company focused on cancer immunotherapy, and as the Vice President of Strategic Ventures for MP3.com, a publicly traded internet and entertainment company. In addition, Mr. Ebel held positions in marketing and corporate development at Amgen, Inc. and began his career as a consultant in the health care practice of the management consulting firm Arthur D. Little. Mr. Ebel received his Bachelor of Science, Magna Cum Laude, from Duke University, and his MBA from the Wharton School at the University of Pennsylvania.

Steve Loomis

Steve Loomis Chief Financial Officer

Steve Loomis joined Colorescience in May 2013 as Chief Financial Officer after three years at SkinMedica, where he served as as Senior Vice President of Finance, Chief Financial Officer and Corporate Secretary. From 1996 to February 2010, Mr. Loomis served as Vice President of Finance, Chief Financial Officer and Corporate Secretary for CardioDynamics International Corporation, a publicly traded international medical device company, and in 2008, he was appointed to the additional role of Vice President of Operations. From 1993 until 1996, he served as Director of Financial Reporting at Kinko's Inc. a worldwide business service provider. From 1988 to 1993, Mr. Loomis was Chief Financial Officer for Terminal Data Corporation, a publicly traded international high technology manufacturing company. He earned his Bachelor's degree in business administration from California State University at Northridge. Mr. Loomis is a certified public accountant and has served on the board of several for-profit and not-for-profit organizations. Mr. Loomis was awarded San Diego Business Journal's 2011 CFO of the Year.


Board of Directors

Josh Baltzell

Josh Baltzell

Josh Baltzell is a Managing Director with Split Rock Partners. He joined the Firm's at its inception in 2005 and provides the healthcare team with an extensive background in the medical device industry, having been involved in virtually all aspects from product development to the acquisition and sale of mature organizations.

Prior to joining Split Rock Partners, Josh served as a Principal with St. Paul Venture Capital's healthcare team, which he joined in 2002. He joined St. Paul Venture Capital from Piper Jaffray where he held the position of vice president in the healthcare investment banking group. During his tenure there, he was involved in a broad range of investment banking activities including private and public equity financings as well as mergers and acquisitions on the buy and sell side.

Prior to joining Piper Jaffray, Josh spent several years in various marketing and business development positions in the medical device industry including vice president, marketing and business development for a medical device start-up and group product manager - emerging technologies for SCIMED/Boston Scientific.

Josh graduated from St. Olaf College and has an MBA from the University of Minnesota's Carlson School of Management.


M Bolyard

M Bolyard

M spent the last 10 years of her full-time career on the retail side as a SVP at ULTA Beauty, first building out the private label strategy and product marketing and then as the lead merchant on the Prestige beauty category, the largest and fastest growing area within ULTA’s portfolio.

M began her business career at Johnson and Johnson in brand management on the TYLENOL franchise.  She transitioned into beauty products marketing at AVON where she was a senior executive on both the US and Global Skin Care business. She also completed an expatriate assignment in Hong Kong focusing on the growing Asian market. 

M returned to J&J first as the VP in charge of developing and launching Neutrogena Cosmetics and then Global VP for the Johnson’s Baby franchise. M serves as Director and/or Advisor to MyChelle Dermaceuticals, butter London Cosmetics and LORAC Cosmetics as well as doing additional consulting on the beauty industry.


David H. Donabedian, Ph.D.

David H. Donabedian, Ph.D.

Dr. Donabedian is a Venture Partner and current Chief Executive Officer and co-founder of Longwood portfolio Company Axial Biotherapeutics. Dr. Donabedian also serves on the Board of Longwood portfolio company Millendo therapeutics. Dr. Donabedian is an accomplished business development and strategy executive with extensive leadership experience and a track record of building companies. Prior to joining Longwood, Dr. Donabedian has held various leadership roles at biopharmaceutical companies including AbbVie (NASDAQ: ABBV) and GSK (NYSE: GSK). At AbbVie, Dr. Donabedian served as Vice President & Global Head of Ventures and Early Stage Collaborations where he led a global team that completed significant transactions across multiple therapeutic areas and stages of development. Prior to AbbVie, Dr. Donabedian served as Vice President Global New Deal Strategy and Development at GlaxoSmithKline, and Senior Manager at Accenture's Strategic Services Consulting Group.

Dr. Donabedian holds a BA in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He currently serves on the Board of Alcyone Life Sciences, a privately held CNS company which he co-founded.


Mary Fisher

Mary Fisher

Mary Fisher is Chair, Chief Executive Officer and Board Director at Colorescience, a former division of SkinMedica Inc., where she served as Chief Executive Officer from 2008 until 2012. She led the successful sale of the company to Allergan, Inc. for $350 million with the potential for another $25 million contingent on certain sales milestones. Ms. Fisher has more than 30 years in the pharmaceutical and biotechnology industries, including management and leadership positions at Acorda Therapeutics, Cephalon, Immunex and Boehringer Ingelheim. She is on the board of directors of Ovascience and MDRejuvena. In 2013, Ms. Fisher was honored as Ernst & Young's Entrepreneur of the Year for San Diego and also received the EY Venture Capital Award of Excellence.


Nicky Kinnaird

Nicky Kinnaird

Nicky Kinnaird is a long-time, esteemed innovator in the beauty industry. She revolutionized retail beauty in the early 1990’s with the launch of Space NK Apothecary in London’s Covent Garden. The ground-breaking boutique featured a curated mix of beauty and wellbeing lines and quickly grew into an international beauty mecca—known for offering consumers a unique selection of the finest established and burgeoning brands. Having stepped down from her Space NK duties over 2 years ago, Kinnaird has fed her passion for the evolution of consumer-focused beauty by consulting on growing brands.


Adele Oliva

Adele Oliva

Adele Oliva brings decades of finance and healthcare experience to 1315 Capital, including 20 years in private equity focused on commercial stage specialty pharmaceutical, medical technology, and healthcare service investments.

Adele co-founded 1315 Capital in 2015 to establish a firm focused on healthcare growth investing. She was recruited to Quaker Partners in 2007 to expand their growth stage investing practice. Prior to Quaker, Adele was Co-Head of US Healthcare at Apax Partners, where she started in 1997.

Forbes recognized Adele on its Midas List of top 100 technology investors worldwide, top 10 life science investors and top women in venture capital.

Adele has served on the board of Ascent Healthcare Solutions (acquired by Stryker), EKR Therapeutics (acquired by Cornerstone Therapeutics), ESP Pharma (acquired by Protein Design Labs), Esprit Pharma (acquired by Allergan), Precision Dermatology (acquired by Valeant), Prometheus Labs (acquired by Nestle) and SkinMedica (acquired by Allergan). She currently serves on the boards of Colorescience, Genoptix, Innovative Health, NovaSom, Onkos Surgical, and TELA Bio.

Prior to entering private equity as a Kauffman Fellow, Adele held roles at CoreStates in commercial banking and Baxter Healthcare in marketing and business development.

Adele received a BSc from St. Joseph’s University and an MBA from Cornell University, where she was awarded the Albert Fried Fellowship.